Genmab A/S (GMAB) Remains Dominant Post EHA - Suntrust

SunTrust analyst Asthika Goonewardene reiterated a Buy rating and $39.00 price target on Genmab A/S (NASDAQ: GMAB) after Darzalex maintained a position of strength after EHA.

The analyst believes data for CD38 rival, Sarclissa, is not strong enough to challenge Darzalex's dominant position and stated "in our view, and we find the competitor's claim that Sarclissa is best-inclass to be a stretch based on the clinical data presented at the European Hematology Association conference (EHA). Despite the competitor study (IKEMA), Dara-Kd has the better data in the key patient cohort (lenrefractory) for these studies. Other data (Andromeda) reinforce adding more to Darzalex's peak potential".

For an analyst ratings summary and ratings history on Genmab A/S click here. For more ratings news on Genmab A/S click here.

Shares of Genmab A/S closed at $30.13 yesterday.

You May Also Be Interested In

• Genmab presents positive EPCORE FL-1 subgroup data for lymphoma treatment
• CFRA Starts SpaceX (SPCX) at Sell, 'Our primary concern is that SpaceX’s long-term strategy remains heavily dependent on Starship'
• Adobe (ADBE) PT Lowered to $225 at UBS Amid Plans to Pivot to Freemium Model